Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C17H23N7O5 |
Molecular Weight | 405.4084 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)C[C@H](NC1=O)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N3CCC[C@H]3C(N)=O
InChI
InChIKey=LQZAIAZUDWIVPM-SRVKXCTJSA-N
InChI=1S/C17H23N7O5/c1-23-13(25)6-10(22-17(23)29)15(27)21-11(5-9-7-19-8-20-9)16(28)24-4-2-3-12(24)14(18)26/h7-8,10-12H,2-6H2,1H3,(H2,18,26)(H,19,20)(H,21,27)(H,22,29)/t10-,11-,12-/m0/s1
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/15931571Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/taltirelin.html | https://www.ncbi.nlm.nih.gov/pubmed/23087672 | https://www.ncbi.nlm.nih.gov/pubmed/25142535
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15931571
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/international/taltirelin.html | https://www.ncbi.nlm.nih.gov/pubmed/23087672 | https://www.ncbi.nlm.nih.gov/pubmed/25142535
Taltirelin (TA-0910), a synthetic thyrotropin-releasing hormone (TRH) analog, has been developed by Tanabe Seiyaku for the treatment of neurodegenerative diseases. Taltirelin mimics the physiological actions of TRH, but with a much longer half-life and duration of effects, and little development of tolerance following prolonged dosing. Taltirelin has nootropic, neuroprotective and analgesic effects. Taltirelin is primarily being researched for the treatment of spinocerebellar ataxia; limited research has also been carried out with regard to other neurodegenerative disorders, e.g., spinal muscular atrophy.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1810 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23087672 |
36.0 nM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Ceredist Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Neuroprotective effect and brain receptor binding of taltirelin, a novel thyrotropin-releasing hormone (TRH) analogue, in transient forebrain ischemia of C57BL/6J mice. | 2002 Dec 20 |
|
Blood-brain permeability of [3H]-(3-methyl-His2)thyrotropin-releasing hormone (MeTRH) in mice: effects of TRH and its analogues. | 2003 |
|
The synthetic TRH analogue taltirelin exerts modality-specific antinociceptive effects via distinct descending monoaminergic systems. | 2007 Feb |
|
Taltirelin is a superagonist at the human thyrotropin-releasing hormone receptor. | 2012 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/15931571
Patients took taltirelin (5 mg bid) or placebo for 28 to 52 weeks.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23087672
HEK-EM 293 (human embryonic kidney) cells stably expressing TRH-R were seeded in black-walled, clear bottomed 96-well plates (Corning, NY, USA) at a density of 60,000 cells/well in DMEM with 10% fetal bovine serum and incubatedfor24hat37◦C in5%CO2. The following day, the culture media was replaced with 100 μl of Hank’s balanced salt solution with 20 mM HEPES, pH 7.5 and the cells were loaded with100 μl of calcium 4 fluorescent dye (Molecular Devices, Sunnyvale, CA, USA) for 1 h at room temperature before addition of compounds .Transient changes in intracellular [Ca++] induced by TALTIRELIN were measured using the FLIPRTETRA system (Molecular Devices, Sunnyvale, CA, USA). Changes in fluorescence were detected at the emission wavelength ranges from 515 to 575 nm. The agonistic responses of ligands were assessed immediately upon their addition in a concentration range from 0.1 nMto30 μM.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C76367
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
TALTIRELIN
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
m10447
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | Merck Index | ||
|
2560
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
7503
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
103300-74-9
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
DOZ62MV6A5
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
C77011
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
114750
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
100000083229
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
SUB10816MIG
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
135653
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
CHEMBL2107016
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY | |||
|
DTXSID0043763
Created by
admin on Sat Dec 16 16:20:17 GMT 2023 , Edited by admin on Sat Dec 16 16:20:17 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SALT/SOLVATE (PARENT)